A device to reduce catheter related bloodstream infection rates in patients with peripherally inserted central catheters (PICCs)
A device to reduce catheter related bloodstream infection rates in patients with peripherally inserted central catheters (PICCs)
批准号:
9410377
负责人:
John E Ashley
金额:
$22.34万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2017
资助国家:
美国
项目状态:
已结题
起止时间:
2017-07-01 至 2017-12-31
关键词:
Accident and Emergency departmentBiological AssayBloodBlood VesselsBurn CentersCandida albicansCaregiversCaringCatheter-related bloodstream infectionCathetersCessation of lifeClinicClinicalComplexDevelopmentDevicesDialysis procedureDiseaseDisinfectionElectronicsEngineeringEscherichia coliEventFDA approvedFood and Drug Administration Device ApprovalGenus staphylococcusGoalsHandHealthcare SystemsHome environmentHospitalsHumanImplantIncentivesIncidenceInfectionInpatientsIntensive Care UnitsInterventional radiologyKlebsiella pneumonia bacteriumLightLiquid substanceMedicalMedical DeviceMercuryMicrobiologyMonitorMorbidity - disease rateNeedlesNursing ProtocolsObservational StudyOperating RoomsOutputPatientsPeripheralPeritoneal DialysisPhasePolymersProcessProtocol ComplianceProtocols documentationProviderPseudomonas aeruginosaSamplingSepsisSmall Business Innovation Research GrantSourceStaphylococcus aureusSterilizationStreamSystemTechniquesTechnologyTestingTimeTreatment CostUnited StatesViolaattributable mortalitybasechemotherapycostdesignexperimental studyinnovationmicroorganismmortalityoptical spectrapatient home careprototypepublic health relevanceresearch clinical testingsealtransmission processverification and validation
中文摘要
摘要
英文摘要
ABSTRACT
PuraCath's goal is to develop an FDA-approved catheter hub disinfection system for peripherally inserted
central catheter (PICC) that dramatically reduces catheter related blood stream infections (CRBSIs) using
LED-Ultra Violet (UV) light. In Phase I of this SBIR project, we propose to optimize the ease of use and
robustness to enable home use. The current CRBSI infection rate is estimated to be between 1.8 to 5.3
CRBSIs/1,000 patient days and costs the provider between $34,508 to $56,000 per CRBSI, with an
attributable mortality rate of 12% to 25% (or each CRBSI. The annual incidence of CRBSIs in the US is
approximately 250,000. This equates to an annual cost on the health care system in the United States alone
of between $8.5 billion and $14 billion. Because the cost of treatment of CRBSI is borne by hospitals and not
Medicare, hospitals have tremendous incentive to minimize incidence of these infections. Patients receiving
chemotherapy frequently have PICC implanted for many months. PICCs require careful cleaning of catheter
connections, which requires a number of complex cleaning steps performed by the patient or their care-giver.
Observational studies have shown the professional care providers have as low as a 35% compliance rate for
proper catheter disinfection protocols, and home care patients often have higher infection rates than inpatient
rates. Our proposed device minimizes time and steps required for catheter cleaning, does not rely on user
technique, and has failsafe sensing capability. Therefore, it is expected to dramatically reduce the CRBSI
rate. PuraCath Medical has already successfully obtained FDA approval for a peritoneal dialysis (PD)
catheter sterilization device that uses mercury lamps to generate UV. While the PD catheter is conceptually
similar, significant technical challenges to adapt this concept for PICC require a distinct commercial
development effort. Technical differences in PICC device that require development include; use of LED to
generate UV, engineering of a needleless connector, and integrated usage monitoring.
Aim 1: To engineer an easy to use, failsafe, and reliable catheter sterilizing device based on UV disinfection
using LED technology.
Aim 2. Design needle-less connector
Aim 3: Conduct microbiologic bench testing.
PuraCath intends to obtain FDA for approval for the device as a 510K, Class 2 device, using PuraCath's PD
device as a predicate.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金